Clinical fracture · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in clinical fracture compared with placebo (moderate certainty).
1 finding from 1 review
Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Death at one year · adults with renal vasculitis
The intervention showed no clear difference in death at one year (low certainty).
1 finding from 1 review
Dialysis · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in dialysis at end of study compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Remission · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in remission at 6 months compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · adults with renal vasculitis
Pulse cyclophosphamide may leads to higher relapse at the end of compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events ‐ treatment failure · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Serious infections · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
Death at 6 months · adults with renal vasculitis
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with renal vasculitis
Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Relapse · adults with renal vasculitis
Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).
1 finding from 1 review
Intervention not reported
Serum creatinine at 1 year · adults with renal vasculitis
1 finding from 1 review